Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

키워드

참고문헌 (53)

1. Kudo M, "JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan", Liver Cancer, 3, pp.458~468 (2014)
2. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
3. Hideki Iwamoto, "Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(3), pp.575~579 (2022), 대한간학회[DOI]
4. Kudo M, "A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma : Asia-Pacific primary liver cancer expert consensus statements", Liver Cancer, 9, pp.245~260 (2020)
5. Jae Seung Lee, "A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea", Clinical and Molecular Hepatology, 26(1), pp.24~32 (2020), 대한간학회
6. Takuji Torimura, "Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects", Clinical and Molecular Hepatology, 27(2), pp.236~245 (2021), 대한간학회[DOI]
7. Shiro Miyayama, "Ultraselective conventional transarterial chemoembolization: When and how?", Clinical and Molecular Hepatology, 25(4), pp.344~353 (2019), 대한간학회
8. Sadahisa Ogasawara, "Switching to systemic therapy after locoregional treatment failure: Definition and best timing", Clinical and Molecular Hepatology, 26(2), pp.155~162 (2020), 대한간학회[DOI]
9. Sang Min Yoon, "Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial", Clinical and Molecular Hepatology, 26(4), pp.506~515 (2020), 대한간학회[DOI]
10. Ho Joong Choi, "Current status and outcome of liver transplantation in South Korea", Clinical and Molecular Hepatology, 28(1), pp.117~119 (2022), 대한간학회[DOI]
11. Ueshima K, "Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment", Liver Cancer, 11, pp.407~425 (2022)
12. Liu M, "Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis", J Gastroenterol Hepatol, 35, pp.1277~1287 (2020)
13. Ando E, "Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis : analysis of 48 cases", Cancer, 95, pp.588~595 (2002)
14. Niizeki T, "Clinical importance of regimens in hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with macrovascular invasion", Cancers(Basel), 13, pp.4450~ (2021)
15. Nagamatsu H, "Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis", Aliment Pharmacol Ther, 32, pp.543~550 (2010)
16. Iwamoto H, "The clinical impact of hepatic arterial infusion chemotherapy New-FP for hepatocellular carcinoma with preserved liver function", Cancers(Basel), 14, pp.4873~ (2022)
17. Omata M, "AsiaPacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
18. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
19. Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
20. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
21. Kudo M, "Management of hepatocellular carcinoma in Japan : JSH Consensus statements and recommendations 2021 update", Liver Cancer, 10, pp.181~223 (2021)
22. Llovet JM, "Prognosis of hepatocellular carcinoma : the BCLC staging classification", Semin Liver Dis, 19, pp.329~338 (1999)
23. Finn RS, "Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
24. Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
25. Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
26. Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma : A phase III, randomized clinical trial(LAUNCH)", J Clin Oncol, 41, pp.117~127 (2023)
27. Kudo M, "Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial", Lancet Gastroenterol Hepatol, 3, pp.424~432 (2018)
28. Choi JH, "Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis", Cancer Chemother Pharmacol, 82, pp.469~478 (2018)
29. He M, "Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion : A randomized clinical trial", JAMA Oncol, 5, pp.953~960 (2019)
30. Zheng K, "Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis : A randomized trial", Radiology, 303, pp.455~464 (2022)
31. Ueshima K, "Clinical practice guidelines for hepatic arterial infusion chemotherapy with a port system proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment", Liver Cancer, 11, pp.407~425 (2022)
32. Kondo M, "Hepatic arterial infusion therapy with a fine powder formulation of cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Jpn J Clin Oncol, 41, pp.69~75 (2011)
33. Ikeda M, "Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma : randomized phase II trial", Ann Oncol, 27, pp.2090~2096 (2016)
34. Nouso K, "Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan", Br J Cancer, 109, pp.1904~1907 (2013)
35. Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 65, pp.373~382 (2010)
36. Ahn Young Eun, "Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis", Gut and Liver, 15(2), pp.284~294 (2021), 거트앤리버 소화기연관학회협의회[DOI]
37. Lee J, "Comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma : A multicenter, propensity score study", J Clin Med, 10, pp.4045~ (2021)
38. 김희언, "A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma", Clinical and Molecular Hepatology, 16(4), pp.355~361 (2010), 대한간학회
39. Obi S, "Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion", Cancer, 106, pp.1990~1997 (2006)
40. Nagamatsu H, "Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma : multicenter phase II study", Cancer Chemother Pharmacol, 77, pp.243~250 (2016)
41. Takayasu K, "Hepatocellular carcinoma : treatment with intraarterial iodized oil with and without chemotherapeutic agents", Radiology, 163, pp.345~351 (1987)
42. Tanaka T, "Efficacy of a glass membrane emulsification device to form mixture of cisplatin powder with lipiodol on transarterial therapy for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 44, pp.766~773 (2021)
43. Shirasaka T, "Mechanism for synergistic antitumor effect in the combination of 5-fluorouracil with cisplatin in vivo tumor models: from the view of biochemical modulation of 5-fluorouracil", Gan To Kagaku Ryoho, 18, pp.403~409 (1991)
44. Hendi M, "Hepatic arterial infusion chemotherapy is a feasible treatment option for hepatocellular carcinoma : A new update", Gastrointest Tumors, 8, pp.145~152 (2021)
45. Haber PK, "Evidence-based management of hepatocellular carcinoma : systematic review and meta-analysis of randomized controlled trials(2002-2020)", Gastroenterology, 161, pp.879~898 (2021)
46. Shimose S, "Multimolecular-targeted agents for intermediate-stage hepatocellular carcinoma influence time to stage progression and overall survival", Oncology, 99, pp.756~765 (2021)
47. Aino H, "Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis", Mol Clin Oncol, 2, pp.393~398 (2014)
48. Nakano M, "Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study", Cancer Med, 4, pp.1836~1843 (2015)
49. Ueshima K, "Hepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma", Liver Cancer, 9, pp.583~595 (2020)
50. Moriguchi M, "Hepatic arterial infusion chemotherapy : A potential therapeutic option for hepatocellular carcinoma with portal vein tumor thrombus", Liver Cancer, 7, pp.209~210 (2018)
51. Sojung Han, "Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma", Clinical and Molecular Hepatology, 26(3), pp.305~308 (2020), 대한간학회
52. Naoshi Nishida, "Long-term prognosis and management of hepatocellular carcinoma after curative treatment", Clinical and Molecular Hepatology, 26(4), pp.480~483 (2020), 대한간학회[DOI]
53. Kondo M, "Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma : SCOOP-2 trial", BMC Cancer, 19, pp.954~ (2019)

관련 논문AI추천